NT

Nutshell Therapeutics at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Nutshell Therapeutics brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on small molecules aimed at the RAS pathway and mutant p53. They cover NTS242, a covalent PI3Kα-RAS disruptor with an AI-generated scaffold, and a preclinical combination of NTS071 with venetoclax in TP53 Y220C-mutated acute myeloid leukemia.

OrganizationENA 2026 Attendance
NT
Nutshell Therapeutics
Shanghai, China
Biotech
Clinical-stage biotech developing allosteric small molecules, including NTS071 for TP53 Y220C-mutant tumours.

Explore the full ENA 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Barcelona. Leave your work email and we’ll be in touch.

Privacy

Download the full ENA 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Nutshell Therapeutics

Tell us what you sell and we’ll find the people at Nutshell Therapeutics most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction